UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
April 27, 2020
electroCore, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 001-38538 | 20-3454976 | ||
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) |
150 Allen Road, Suite 201
Basking Ridge, NJ 07920
(Address of principal executive offices and zip code)
(973)290-0097
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) | |
☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) | |
☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
|
|
| ||
Common Stock, Par Value $0.001 Per Share | ECOR | NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01. | Other Events |
On April 27, 2020, electroCore, Inc. (the “Company”) issued a press release with an update on the Company’s ongoingnon-invasive vagus nerve stimulation initiatives related toCOVID-19, including the commencement of enrollment ofCOVID-19 patients in an investigator-initiated, randomized, controlled clinical trial of nVNS therapy in Spain.
The Company also announced that a paper, entitled “Use ofNon-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated withCOVID-19: A Theoretical Hypothesis and Early Clinical Experience” has gone through peer review and been accepted for publication by the journalNeuromodulation: Technology at the Neural Interface. The paper is available at https://onlinelibrary.wiley.com/doi/abs/10.1111/ner.13172.
A copy of the press release is filed with this Form8-K as Exhibit 99.1.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. | Description of Exhibit | |
99.1 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
electroCore, Inc.
| ||
May 1, 2020 | /s/ Brian Posner | |
| ||
Brian Posner | ||
Chief Financial Officer |